The biannual Hemoglobin Switching Conference has been ongoing for 37 years, and there are multiple reasons for its resounding success. First and foremost, the organizers (Stamatoyannopoulos, Higgs and Engel) strive to identify and then highlight new discoveries by always including new investigators and studies that impinge on the process of hemoglobin switching. Second, this is the only venue (other than the annual ASH meeting, with more than 14,000 attendees) that brings together basic scientists and clinicians to discuss both the molecular and developmental origins of, and treatments for, hemoglobinopathies. Third, the meetings have historically morphed into focusing on wherever the science led, thus remaining extremely topical, and has not only been the forum for presenting the first cDNA clones, the first cloned human genomic locus (and the first mutations in same), the structure of erythropoietin, but it has also launched the careers of many of the current leaders in this field (indeed, numerous postdoctoral fellows and young faculty first presented their work in plenary sessions at this conference). Fourth, this is the only meeting on this topic that routinely has approximatel equal attendance by investigators from both inside and outside the U.S., and this fact is reflected by the bi-annual alternation in site between the U.S. and Europe. In 2014 the Conference will again be held at St. Johns College at Oxford University in Oxford, England, because of both international accessibility and economy.

Public Health Relevance

The most commonly inherited human genetic disorders are hemoglobinopathies, diseases that disrupt the function of the red blood cells that carry oxygen to tissues that execute basic metabolism and that also carry waste products and metabolites back to the lungs for exchange for fresh oxygen. We now understand a great deal about the origins of these metabolic diseases from a genetic and biochemical perspective, but we are only beginning to understand how we might devise effective therapies to treat them. This international conference, held every two years alternating between Europe and the U.S.A., is the only meeting of its kind, and provides a forum for sharing information between molecular and cell biologists who study disease characteristics and etiology and their clinical counterparts who treat these diseases. This conference is consciously more inclusive of young people, women and minority participation than any other forum. (End of Abstract)

Agency
National Institute of Health (NIH)
Type
Conference (R13)
Project #
1R13HL124909-01
Application #
8785769
Study Section
Special Emphasis Panel (ZHL1)
Program Officer
Chang, Henry
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Anatomy/Cell Biology
Type
Schools of Medicine
DUNS #
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109